Pfizer Inc (PFE) 34.34 $PFE
Fed Meeting, Twitter Earnings, Consumer Data in Focus Tuesday
at The Street - Mon Jul 27, 7:15PM CDT
Merck, Pfizer, UPS and Twitter are among the many companies reporting earnings.
F: 14.55 (+0.16), PNRA: 184.01 (+0.80), GILD: 110.54 (-2.29), PFE: 34.34 (+0.08), MRK: 56.99 (-0.42), DD: 56.73 (-0.21), TWTR: 34.70 (-0.72), BWLD: 168.57 (-1.00), UPS: 95.12 (+0.37)
What's in Store for Hospira (HSP) this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 3:20PM CDT
Hospira Inc. (HSP) is set to report second-quarter 2015 results on Jul 29 before the market opens.
IMDZ: 23.13 (-0.14), MDCO: 33.39 (-0.43), PFE: 34.34 (+0.08), HSP: 89.35 (+0.10)
Will Currency & Generics Weigh on Pfizer (PFE) Q2 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 3:10PM CDT
Pfizer (PFE), which is scheduled to report its second-quarter 2015 earnings on Jul 28, had posted a positive earnings surprise of 2.00% last quarter.
MDCO: 33.39 (-0.43), PFE: 34.34 (+0.08), TEVA: 72.00 (+10.15), HSP: 89.35 (+0.10)
Will Headwinds Weigh on Glaxo's (GSK) Earnings in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 2:50PM CDT
Glaxo (GSK), which is scheduled to report its second-quarter 2015 earnings on Jul 29, had posted a negative earnings surprise of 12.73% last quarter.
PRGO: 193.60 (+7.10), PFE: 34.34 (+0.08), GSK: 41.60 (+0.21), NVS: 101.54 (-0.26)
Pfizer (PFE) Stock Falls Ahead of Earnings Release
at The Street - Mon Jul 27, 10:43AM CDT
Pfizer (PFE) shares are declining ahead of tomorrow's release of the company's second quarter earnings results.
PFE: 34.34 (+0.08)
Norfolk Southern, Roper Industries, Pfizer, Merck and IBM are part of Zacks Earnings Preview: - Press Releases
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 8:30AM CDT
Norfolk Southern, Roper Industries, Pfizer, Merck and IBM are part of Zacks Earnings Preview:
ROP: 164.25 (-7.86), MRK: 56.99 (-0.42), PFE: 34.34 (+0.08), DD: 56.73 (-0.21)
Brain Hemorrhage - Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/64tx7w/brain_hemorrhage) has announced the addition of the "Brain Hemorrhage Global Clinical Trials Review, H1, 2015" report to their offering. "Brain Hemorrhage Global Clinical Trials Review, H1, 2015" provides data on the Brain Hemorrhage clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Brain Hemorrhage. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Brain Hemorrhage. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Brain Hemorrhage Therapeutics Clinical Trials - Novo A/S - Shenzhen Hornetcorn Bio-technology Company, Ltd. - Pfizer Inc. - Octapharma AG - GlaxoSmithKline plc - BTG plc - AstraZeneca PLC - Arbor Pharmaceuticals, LLC. - The Johns Hopkins University - China Medical University Hospital - Kawasaki Medical School Hospital - McMaster University - Oriental Neurosurgery Evidence-Based-Study Team - Seoul National University Hospital - Sunnybrook Health Sciences Centre - The George Institute for Global Health - Thomas Jefferson University For more information visit http://www.researchandmarkets.com/research/64...hemorrhage
PFE: 34.34 (+0.08), AZN: 32.71 (-33.05), GSK: 41.60 (+0.21)
Appendicitis Clinical Trials - Global Review, H1, 2015
M2 - Mon Jul 27, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ltzv2k/appendicitis) has announced the addition of the "Appendicitis Global Clinical Trials Review, H1, 2015" report to their offering. "Appendicitis Global Clinical Trials Review, H1, 2015" provides data on the Appendicitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Appendicitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Appendicitis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Appendicitis Therapeutics Clinical Trials - Johnson & Johnson - Pfizer Inc. - The Children's Mercy Hospital - University of California, San Diego - Academic Medical Center - HaEmek Medical Center - Karolinska University Hospital - Kashan University of Medical Sciences and Health Services - Nationwide Children's Hospital - Assistance Publique - Hopitaux de Paris - Centre Hospitalier Universitaire de Nantes - Centre Hospitalier Universitaire, Amiens For more information visit http://www.researchandmarkets.com/research/lt...pendicitis
JNJ: 98.28 (-0.87), PFE: 34.34 (+0.08)
Neuroendocrine Carcinoma - Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 6:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s9llfs/neuroendocrine) has announced the addition of the "Neuroendocrine Carcinoma Global Clinical Trials Review, H1, 2015" report to their offering. "Neuroendocrine Carcinoma Global Clinical Trials Review, H1, 2015" provides data on the Neuroendocrine Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuroendocrine Carcinoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuroendocrine Carcinoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Neuroendocrine Carcinoma Therapeutics Clinical Trials - Pfizer Inc. - Novartis AG - Philogen S.p.A. - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Fondazione IRCCS - Istituto Nazionale dei Tumori - Japan Clinical Oncology Group - Alberta Health Services - Centre Hospitalier Universitaire de Grenoble - Chiba University - Gabrail Cancer Center For more information visit http://www.researchandmarkets.com/research/s9...oendocrine
PFE: 34.34 (+0.08), NVS: 101.54 (-0.26)
3 Questions Wall Street Wants Answered When Pfizer Reports Q2 Results
Sean Williams, The Motley Fool - Motley Fool - Mon Jul 27, 6:03AM CDT
Source: Pfizer via Facebook. Earnings season is now well under way, and one of the most important reports in the pharmaceutical sector is right around the corner: Pfizer . The Big Pharma kingpin is set to report its results before the opening...
PFE: 34.34 (+0.08)
A look at the largest companies in the S&P 500
By The Associated Press - AP - Fri Jul 24, 6:08PM CDT
Amazon surpassed the world's largest retailer, Wal-Mart Stores Inc., in market value Friday, on the back of a strong earnings report. Amazon shares closed up nearly 10 percent, giving the Seattle company a market value of $247.77 billion, versus $230.53 billion for Wal-Mart.
AMZN: 531.41 (+1.99), GE: 25.95 (+0.20), FB: 94.17 (-2.78), PFE: 34.34 (+0.08), DIS: 118.25 (-0.66), WMT: 71.38 (-0.20), XOM: 79.26 (-0.68), BAC: 17.67 (-0.23), WFC: 57.59 (-0.19), GOOG: 627.26 (+3.70), JNJ: 98.28 (-0.87), GOOGL: 658.27 (+3.50), PG: 79.97 (-0.32), MSFT: 45.35 (-0.59), AAPL: 122.77 (-1.73)
FDA OKs breakthrough cholesterol drug for high-risk patients
By MATTHEW PERRONE - AP - Fri Jul 24, 5:31PM CDT
WASHINGTON (AP) — The Food and Drug Administration on Friday approved a first-of-a-kind drug that lowers artery-clogging cholesterol more than older drugs that have been prescribed for decades.
PFE: 34.34 (+0.08), AMGN: 165.54 (+6.95), REGN: 540.03 (-1.82)
SmarTrend Watching for Potential Rebound in Shares of Pfizer After 1.50% Loss
Comtex SmarTrend(R) - Fri Jul 24, 4:49PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $34.15 to a high of $34.72. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $34.63 on volume of 21.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
PFE: 34.34 (+0.08)
After Yesterday's Decline of 1.50%, Pfizer Offers Investors Better Value
Comtex SmarTrend(R) - Fri Jul 24, 4:48PM CDT
Pfizer (NYSE FE) traded in a range yesterday that spanned from a low of $34.15 to a high of $34.72. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $34.63 on volume of 21.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
PFE: 34.34 (+0.08)
Regeneron/Sanofi PCSK9 Cholesterol Drug Wins FDA OK
at Investor's Business Daily - Fri Jul 24, 4:24PM CDT
Praluent, the new cholesterol-busting drug from Regeneron Pharmaceuticals (REGN) and Sanofi (SNY), was granted FDA approval Friday, but for a slightly more limited patient pool than some had hoped. Regeneron stock closed down 2.7% to 541.85 on the...
ESPR: 71.65 (-4.26), MDCO: 33.39 (-0.43), PFE: 34.34 (+0.08), AMGN: 165.54 (+6.95), SNY: 53.33 (-0.21), REGN: 540.03 (-1.82)
Earnings Growth Hard to Come By - Earnings Preview
Sheraz Mian - Zacks Investment Research - Fri Jul 24, 2:35PM CDT
Earnings Growth Hard to Come By - Earnings Preview
WFM: 40.16 (-0.27), ROP: 164.25 (-7.86), FB: 94.17 (-2.78), PFE: 34.34 (+0.08), IP: 47.36 (-0.39), AMGN: 165.54 (+6.95), COP: 50.65 (-1.44), XOM: 79.26 (-0.68), UPS: 95.12 (+0.37), MRK: 56.99 (-0.42), EXPE: 104.92 (-0.78), DD: 56.73 (-0.21), PG: 79.97 (-0.32), CVX: 89.14 (-1.46), MA: 94.39 (-1.44)
Pfizer (PFE) Approaches New Downside Target of $34.43
Comtex SmarTrend(R) - Fri Jul 24, 9:35AM CDT
Pfizer (NYSE FE) has opened bearishly below the pivot of $34.80 today and has reached the first level of support at $34.60. Should the shares continue to fall, the support pivots of $34.43 and $34.05 will be of interest.
PFE: 34.34 (+0.08)
Don't Sell Qualcomm; Stick With Companies That Have Growth
at The Street - Thu Jul 23, 2:04PM CDT
The CNBC 'Fast Money' traders debate whether now is a good time to sell Qualcomm, and discuss a raft of other stocks.
AMZN: 531.41 (+1.99), NKE: 111.73 (-1.26), FB: 94.17 (-2.78), PFE: 34.34 (+0.08), C: 57.96 (-0.74), LLY: 84.15 (-0.57), BMY: 64.30 (-1.68), INTC: 28.35 (+0.29), HPQ: 30.25 (-0.56), FINL: 26.83 (-0.11), NFLX: 106.43 (-2.91), UA: 96.43 (+0.38), JPM: 68.01 (-0.90), IBM: 159.07 (-0.68), QCOM: 61.98 (+0.34), FFIV: 127.81 (+0.32), CRUS: 32.90 (-1.31), GOOGL: 658.27 (+3.50), FL: 68.79 (-0.64), AAPL: 122.77 (-1.73), FTNT: 47.10 (-0.89), CSCO: 28.21 (-0.19)
Bristol-Myers Beats on Q2 Earnings, Raises 2015 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 12:32PM CDT
Bristol-Myers Squibb Company's (BMY) second-quarter 2015 earnings (excluding special items) of 53 cents per share beat the Zacks Consensus Estimate of 35 cents.
PFE: 34.34 (+0.08), SNSS: 1.05 (+0.09), AMAG: 65.07 (-5.37), BMY: 64.30 (-1.68)
Fed Meeting, Twitter Earnings, Consumer Data in Focus Tuesday
at The Street - Mon Jul 27, 7:15PM CDT
Merck, Pfizer, UPS and Twitter are among the many companies reporting earnings.
F: 14.55 (+0.16), PNRA: 184.01 (+0.80), GILD: 110.54 (-2.29), PFE: 34.34 (+0.08), MRK: 56.99 (-0.42), DD: 56.73 (-0.21), TWTR: 34.70 (-0.72), BWLD: 168.57 (-1.00), UPS: 95.12 (+0.37)
What's in Store for Hospira (HSP) this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 3:20PM CDT
Hospira Inc. (HSP) is set to report second-quarter 2015 results on Jul 29 before the market opens.
IMDZ: 23.13 (-0.14), MDCO: 33.39 (-0.43), PFE: 34.34 (+0.08), HSP: 89.35 (+0.10)
Will Currency & Generics Weigh on Pfizer (PFE) Q2 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 3:10PM CDT
Pfizer (PFE), which is scheduled to report its second-quarter 2015 earnings on Jul 28, had posted a positive earnings surprise of 2.00% last quarter.
MDCO: 33.39 (-0.43), PFE: 34.34 (+0.08), TEVA: 72.00 (+10.15), HSP: 89.35 (+0.10)
Will Headwinds Weigh on Glaxo's (GSK) Earnings in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 2:50PM CDT
Glaxo (GSK), which is scheduled to report its second-quarter 2015 earnings on Jul 29, had posted a negative earnings surprise of 12.73% last quarter.
PRGO: 193.60 (+7.10), PFE: 34.34 (+0.08), GSK: 41.60 (+0.21), NVS: 101.54 (-0.26)
Pfizer (PFE) Stock Falls Ahead of Earnings Release
at The Street - Mon Jul 27, 10:43AM CDT
Pfizer (PFE) shares are declining ahead of tomorrow's release of the company's second quarter earnings results.
PFE: 34.34 (+0.08)
Norfolk Southern, Roper Industries, Pfizer, Merck and IBM are part of Zacks Earnings Preview: - Press Releases
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 8:30AM CDT
Norfolk Southern, Roper Industries, Pfizer, Merck and IBM are part of Zacks Earnings Preview:
ROP: 164.25 (-7.86), MRK: 56.99 (-0.42), PFE: 34.34 (+0.08), DD: 56.73 (-0.21)
Brain Hemorrhage - Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/64tx7w/brain_hemorrhage) has announced the addition of the "Brain Hemorrhage Global Clinical Trials Review, H1, 2015" report to their offering. "Brain Hemorrhage Global Clinical Trials Review, H1, 2015" provides data on the Brain Hemorrhage clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Brain Hemorrhage. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Brain Hemorrhage. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Brain Hemorrhage Therapeutics Clinical Trials - Novo A/S - Shenzhen Hornetcorn Bio-technology Company, Ltd. - Pfizer Inc. - Octapharma AG - GlaxoSmithKline plc - BTG plc - AstraZeneca PLC - Arbor Pharmaceuticals, LLC. - The Johns Hopkins University - China Medical University Hospital - Kawasaki Medical School Hospital - McMaster University - Oriental Neurosurgery Evidence-Based-Study Team - Seoul National University Hospital - Sunnybrook Health Sciences Centre - The George Institute for Global Health - Thomas Jefferson University For more information visit http://www.researchandmarkets.com/research/64...hemorrhage
PFE: 34.34 (+0.08), AZN: 32.71 (-33.05), GSK: 41.60 (+0.21)
Appendicitis Clinical Trials - Global Review, H1, 2015
M2 - Mon Jul 27, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ltzv2k/appendicitis) has announced the addition of the "Appendicitis Global Clinical Trials Review, H1, 2015" report to their offering. "Appendicitis Global Clinical Trials Review, H1, 2015" provides data on the Appendicitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Appendicitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Appendicitis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Appendicitis Therapeutics Clinical Trials - Johnson & Johnson - Pfizer Inc. - The Children's Mercy Hospital - University of California, San Diego - Academic Medical Center - HaEmek Medical Center - Karolinska University Hospital - Kashan University of Medical Sciences and Health Services - Nationwide Children's Hospital - Assistance Publique - Hopitaux de Paris - Centre Hospitalier Universitaire de Nantes - Centre Hospitalier Universitaire, Amiens For more information visit http://www.researchandmarkets.com/research/lt...pendicitis
JNJ: 98.28 (-0.87), PFE: 34.34 (+0.08)
Neuroendocrine Carcinoma - Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 6:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s9llfs/neuroendocrine) has announced the addition of the "Neuroendocrine Carcinoma Global Clinical Trials Review, H1, 2015" report to their offering. "Neuroendocrine Carcinoma Global Clinical Trials Review, H1, 2015" provides data on the Neuroendocrine Carcinoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuroendocrine Carcinoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuroendocrine Carcinoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Neuroendocrine Carcinoma Therapeutics Clinical Trials - Pfizer Inc. - Novartis AG - Philogen S.p.A. - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Fondazione IRCCS - Istituto Nazionale dei Tumori - Japan Clinical Oncology Group - Alberta Health Services - Centre Hospitalier Universitaire de Grenoble - Chiba University - Gabrail Cancer Center For more information visit http://www.researchandmarkets.com/research/s9...oendocrine
PFE: 34.34 (+0.08), NVS: 101.54 (-0.26)
3 Questions Wall Street Wants Answered When Pfizer Reports Q2 Results
Sean Williams, The Motley Fool - Motley Fool - Mon Jul 27, 6:03AM CDT
Source: Pfizer via Facebook. Earnings season is now well under way, and one of the most important reports in the pharmaceutical sector is right around the corner: Pfizer . The Big Pharma kingpin is set to report its results before the opening...
PFE: 34.34 (+0.08)
A look at the largest companies in the S&P 500
By The Associated Press - AP - Fri Jul 24, 6:08PM CDT
Amazon surpassed the world's largest retailer, Wal-Mart Stores Inc., in market value Friday, on the back of a strong earnings report. Amazon shares closed up nearly 10 percent, giving the Seattle company a market value of $247.77 billion, versus $230.53 billion for Wal-Mart.
AMZN: 531.41 (+1.99), GE: 25.95 (+0.20), FB: 94.17 (-2.78), PFE: 34.34 (+0.08), DIS: 118.25 (-0.66), WMT: 71.38 (-0.20), XOM: 79.26 (-0.68), BAC: 17.67 (-0.23), WFC: 57.59 (-0.19), GOOG: 627.26 (+3.70), JNJ: 98.28 (-0.87), GOOGL: 658.27 (+3.50), PG: 79.97 (-0.32), MSFT: 45.35 (-0.59), AAPL: 122.77 (-1.73)
FDA OKs breakthrough cholesterol drug for high-risk patients
By MATTHEW PERRONE - AP - Fri Jul 24, 5:31PM CDT
WASHINGTON (AP) — The Food and Drug Administration on Friday approved a first-of-a-kind drug that lowers artery-clogging cholesterol more than older drugs that have been prescribed for decades.
PFE: 34.34 (+0.08), AMGN: 165.54 (+6.95), REGN: 540.03 (-1.82)
SmarTrend Watching for Potential Rebound in Shares of Pfizer After 1.50% Loss
Comtex SmarTrend(R) - Fri Jul 24, 4:49PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $34.15 to a high of $34.72. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $34.63 on volume of 21.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. PFE: 34.34 (+0.08)
After Yesterday's Decline of 1.50%, Pfizer Offers Investors Better Value
Comtex SmarTrend(R) - Fri Jul 24, 4:48PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $34.15 to a high of $34.72. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $34.63 on volume of 21.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. PFE: 34.34 (+0.08)
Regeneron/Sanofi PCSK9 Cholesterol Drug Wins FDA OK
at Investor's Business Daily - Fri Jul 24, 4:24PM CDT
Praluent, the new cholesterol-busting drug from Regeneron Pharmaceuticals (REGN) and Sanofi (SNY), was granted FDA approval Friday, but for a slightly more limited patient pool than some had hoped. Regeneron stock closed down 2.7% to 541.85 on the...
ESPR: 71.65 (-4.26), MDCO: 33.39 (-0.43), PFE: 34.34 (+0.08), AMGN: 165.54 (+6.95), SNY: 53.33 (-0.21), REGN: 540.03 (-1.82)
Earnings Growth Hard to Come By - Earnings Preview
Sheraz Mian - Zacks Investment Research - Fri Jul 24, 2:35PM CDT
Earnings Growth Hard to Come By - Earnings Preview
WFM: 40.16 (-0.27), ROP: 164.25 (-7.86), FB: 94.17 (-2.78), PFE: 34.34 (+0.08), IP: 47.36 (-0.39), AMGN: 165.54 (+6.95), COP: 50.65 (-1.44), XOM: 79.26 (-0.68), UPS: 95.12 (+0.37), MRK: 56.99 (-0.42), EXPE: 104.92 (-0.78), DD: 56.73 (-0.21), PG: 79.97 (-0.32), CVX: 89.14 (-1.46), MA: 94.39 (-1.44)
Pfizer (PFE) Approaches New Downside Target of $34.43
Comtex SmarTrend(R) - Fri Jul 24, 9:35AM CDT
Pfizer (NYSE
FE) has opened bearishly below the pivot of $34.80 today and has reached the first level of support at $34.60. Should the shares continue to fall, the support pivots of $34.43 and $34.05 will be of interest. PFE: 34.34 (+0.08)
Don't Sell Qualcomm; Stick With Companies That Have Growth
at The Street - Thu Jul 23, 2:04PM CDT
The CNBC 'Fast Money' traders debate whether now is a good time to sell Qualcomm, and discuss a raft of other stocks.
AMZN: 531.41 (+1.99), NKE: 111.73 (-1.26), FB: 94.17 (-2.78), PFE: 34.34 (+0.08), C: 57.96 (-0.74), LLY: 84.15 (-0.57), BMY: 64.30 (-1.68), INTC: 28.35 (+0.29), HPQ: 30.25 (-0.56), FINL: 26.83 (-0.11), NFLX: 106.43 (-2.91), UA: 96.43 (+0.38), JPM: 68.01 (-0.90), IBM: 159.07 (-0.68), QCOM: 61.98 (+0.34), FFIV: 127.81 (+0.32), CRUS: 32.90 (-1.31), GOOGL: 658.27 (+3.50), FL: 68.79 (-0.64), AAPL: 122.77 (-1.73), FTNT: 47.10 (-0.89), CSCO: 28.21 (-0.19)
Bristol-Myers Beats on Q2 Earnings, Raises 2015 Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 23, 12:32PM CDT
Bristol-Myers Squibb Company's (BMY) second-quarter 2015 earnings (excluding special items) of 53 cents per share beat the Zacks Consensus Estimate of 35 cents.
PFE: 34.34 (+0.08), SNSS: 1.05 (+0.09), AMAG: 65.07 (-5.37), BMY: 64.30 (-1.68)
